Fig. 3: Development of paclitaxome-2 with a built-in ultra-pH-sensitive probe to trigger cationization-induced transcytosis in tumors. | Nature Cancer

Fig. 3: Development of paclitaxome-2 with a built-in ultra-pH-sensitive probe to trigger cationization-induced transcytosis in tumors.

From: A sphingolipid-derived paclitaxel nanovesicle enhances efficacy of combination therapies in triple-negative breast cancer and pancreatic cancer

Fig. 3: Development of paclitaxome-2 with a built-in ultra-pH-sensitive probe to trigger cationization-induced transcytosis in tumors.

a, Synthesis of SM–AZO–PTX and SM–AZE–PTX. b, the representative distribution of DLS size via intensity for AZO– and AZE–paclitaxome-2 (n = 3 independent experiments per group). c,d, The DLS size presented as intensity (c) and Zeta potential (d) for AZO– and AZE–paclitaxome-2 monitored over 2 weeks in 5% dextrose at 4 °C. e, Schematic of transcytosis in tumors. f, Zeta potential at different pH. g,h, Representative flow cytometry histogram of cellular uptake (g, n = 3 biological replicates per group) and quantitative determination (h, n = 3 biological replicates per group) for various DSPE–Cy5-labeled paclitaxome-2 under different pH conditions in 4T1-Luc2 cells. Data are presented as mean ± s.d. within c, d, f and h (n = 3 independent experiments per group). One-way ANOVA with Tukey’s multiple comparisons test were used to calculate the exact P values in the statistical analyses.

Source data

Back to article page